Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-HYPERION: IL-6 in TTM after non-shockable cardiac arrest
NCT02711098Phase 3Completed
- Sponsor
- CHD Vendée
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cardiac arrest (SCA) (2 arms), sponsored by CHD Vendée. Primary endpoint: Interleukine 6 at 72 hours. Started Mar 2016; status: completed.
02
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT02711098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711098.